References
- Aljiffry M, Walsh MJ, Molinari M (2009). Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009. World J Gastroenterol, 15, 4240-62. https://doi.org/10.3748/wjg.15.4240
- Bartlett DL, Fong Y, Fortner JG, et al (1996). Long-term results after resection for gallbladder cancer. Implications for staging and management. Ann Surg, 224, 639-46. https://doi.org/10.1097/00000658-199611000-00008
- Dixon E, Vollmer CM Jr, Sahajpal A, et al (2005). An aggressive surgical approach leads to improved survival in patients with gallbladder cancer: a 12-year study at a North American Center. Ann Surg, 241, 385-94. https://doi.org/10.1097/01.sla.0000154118.07704.ef
- Hueman MT, Vollmer CM Jr, Pawlik TM (2009). Evolving treatment strategies for gallbladder cancer. Ann Surg Oncol, 16, 2101-15. https://doi.org/10.1245/s10434-009-0538-x
- Lazcano-Ponce EC, Miquel JF, Munoz N, et al (2001). Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin, 51, 349-64. https://doi.org/10.3322/canjclin.51.6.349
- Onori P, Gaudio E, Franchitto A, et al (2010). Histamine regulation of hyperplastic and neoplastic cell growth in cholangiocytes. World J Gastrointest Pathophysiol, 1, 38-49. https://doi.org/10.4291/wjgp.v1.i2.38
- Patel T (2002). Worldwide trends in mortality from biliary tract malignancies. BMC Cancer, 2, 10. https://doi.org/10.1186/1471-2407-2-10
- de Groen PC, Gores GJ, LaRusso NF, et al (1999). Biliary tract cancers. N Engl J Med, 341, 1368-78. https://doi.org/10.1056/NEJM199910283411807
- Patel T (2004). Worldwide trends in mortality from biliary tract malignancies. BMC Cancer, 2, 10.
- Rajagopalan H, Lengauer C (2004). Aneuploidy and cancer. Nature, 432, 338-41. https://doi.org/10.1038/nature03099
- Randi G, Franceschi S, La Vecchia C (2006). Gallbladder cancer worldwide: geographical distribution and risk factors. Int J Cancer, 118, 1591-602. https://doi.org/10.1002/ijc.21683
- Shrikhande SV, Barreto SG, Singh S, et al (2010). Cholelithiasis in gallbladder cancer: coincidence, cofactor, or cause! Eur J Surg Oncol, 36, 514-9. https://doi.org/10.1016/j.ejso.2010.05.002
- Song SC, Heo JS, Choi DW, et al (2011). Survival benefits of surgical resection in recurrent cholangiocarcinoma. J Korean Surg Soc, 81, 187-94. https://doi.org/10.4174/jkss.2011.81.3.187
- Welzel TM, McGlynn KA, Hsing AW, et al (2006). Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst, 98, 873-5. https://doi.org/10.1093/jnci/djj234
- Wistuba II, Gazdar AF (2004). Gallbladder cancer: lessons from a rare tumour. Nat Rev Cancer, 4, 695-706. https://doi.org/10.1038/nrc1429
- Wolpin BM, Mayer RJ (2010). A step forward in the treatment of advanced biliary tract cancer. N Engl J Med, 362, 1335-7. https://doi.org/10.1056/NEJMe1001183
Cited by
- Platelet Derived Growth Factor-B and Human Epidermal Growth Factor Receptor-2 Polymorphisms in Gall Bladder Cancer vol.16, pp.14, 2015, https://doi.org/10.7314/APJCP.2015.16.14.5647
- Application of Joint Detection of AFP, CA19-9, CA125 and CEA in Identification and Diagnosis of Cholangiocarcinoma vol.16, pp.8, 2015, https://doi.org/10.7314/APJCP.2015.16.8.3451
- Therapeutic outcomes and prognostic factors in unresectable gallbladder cancer treated with gemcitabine plus cisplatin vol.19, pp.1, 2019, https://doi.org/10.1186/s12885-018-5211-y